New therapeutic target for treating nonalcoholic steatohepatitis (NASH) and fatty liver disease
- 總結
- Rudolph L Leibel, M.D.
- 技術優勢
- Provides a target for NASH therapeutic developmentProvides a target for dyslipidemia therapeutic developmentPatent information:N/ATech Ventures Reference: IR CU13175
- 技術應用
- Pharmaceutical activators of ILDR2 may reduce lipid accumulation in the liver to treat NASH patients.ILDR2 alters lipoprotein metabolism and may be used to treat dyslipidemia and atherosclerosis. Characterization of ILDR2 suggests a role in preservation of beta cell mass, and control of body weight.
- 詳細技術說明
- Rudolph L Leibel, M.D.
- *Abstract
-
None
- *Inquiry
- Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU13175
- *Principal Investigation
-
- *Publications
- Watanabe K, Watson E, Cremona ML, Millings EJ, Lefkowitch JH, Fischer SG, LeDuc CA, Leibel RL. (2013) ILDR2: an endoplasmic reticulum resident molecule mediating hepatic lipid homeostasis. PLoS One. Vol 8(6):e67234.
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
